References

1. I. H. i. R. N. Consortium, The Integrative Human Microbiome Project. Nature 569, 641-648 (2019).

2. H. M. P. Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012).

3. M. G. Dominguez-Bello et al., Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 107, 11971-11975 (2010).

4. K. Oliphant, E. Allen-Vercoe, Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 7, 91 (2019).

5. J. M. Pickard, M. Y. Zeng, R. Caruso, G. Núñez, Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev 279, 70-89 (2017).

6. Y. Belkaid, T. W. Hand, Role of the microbiota in immunity and inflammation. Cell 157, 121-141 (2014).

7. C. B. Lambring et al., Impact of the Microbiome on the Immune System. Crit Rev Immunol 39, 313-328 (2019).

8. J. Manos, The human microbiome in disease and pathology. APMIS 130, 690-705 (2022).

9. K. Honda, D. R. Littman, The microbiota in adaptive immune homeostasis and disease. Nature 535, 75-84 (2016).

10. K. Peebles, J. Velloza, J. E. Balkus, R. S. McClelland, R. V. Barnabas, High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis 46, 304-311 (2019).

11. L. R. McKinnon et al., The evolving facets of bacterial vaginosis: implications for HIV transmission. AIDS Res Hum Retroviruses, (2019).

12. P. Bagnall, D. Rizzolo, Bacterial vaginosis: A practical review. JAAPA 30, 15-21 (2017).

13. F. Zegers-Hochschild et al., The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod 32, 1786-1801 (2017).

14. M. Vander Borght, C. Wyns, Fertility and infertility: Definition and epidemiology. Clin Biochem 62, 2-10 (2018).

15. R. D. Burk, A. Harari, Z. Chen, Human papillomavirus genome variants. Virology 445, 232-243 (2013).

16. Z. Chen et al., Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516, 86-101 (2018).

17. J. D. Nash, T. W. Burke, W. J. Hoskins, Biologic course of cervical human papillomavirus infection. Obstet Gynecol 69, 160-162 (1987).

18. C. A. Thaiss, N. Zmora, M. Levy, E. Elinav, The microbiome and innate immunity. Nature 535, 65-74 (2016).

19. M. Di Paola et al., Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci Rep 7, 10200 (2017).

20. J. E. Lee et al., Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One 8, e63514 (2013).

21. B. Shannon et al., Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol 10, 1310-1319 (2017).

22. R. M. Brotman et al., Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis 210, 1723-1733 (2014).

23. J. van Schalkwyk, M. H. Yudin, I. D. COMMITTEE, Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. J Obstet Gynaecol Can 37, 266-274 (2015).

24. M. Sojakova, D. Liptajova, M. Borovsky, J. Subik, Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 157, 163-169 (2004).

25. J. E. Bilardi et al., The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 8, e74378 (2013).

26. J. Atashili, C. Poole, P. M. Ndumbe, A. A. Adimora, J. S. Smith, Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 22, 1493-1501 (2008).

27. J. A. Svare, H. Schmidt, B. B. Hansen, G. Lose, Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG 113, 1419-1425 (2006).

28. E. A. Torrone et al., Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med 15, e1002511 (2018).

29. L. Myer et al., Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 192, 1372-1380 (2005).

30. T. E. Taha et al., Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12, 1699-1706 (1998).

31. L. Myer, L. Kuhn, Z. A. Stein, T. C. Wright, Jr., L. Denny, Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 5, 786-794 (2005).

32. L. R. McKinnon et al., The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. AIDS Res Hum Retroviruses 35, 219-228 (2019).

33. H. Leitich, H. Kiss, Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 21, 375-390 (2007).

34. M. N. Anahtar, D. B. Gootenberg, C. M. Mitchell, D. S. Kwon, Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell Host Microbe 23, 159-168 (2018).

35. B. M. Mercer et al., The Preterm Prediction Study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 183, 738-745 (2000).

36. S. J. Kroon, J. Ravel, W. M. Huston, Cervicovaginal microbiota, women's health, and reproductive outcomes. Fertil Steril 110, 327-336 (2018).

37. F. Bradley et al., The vaginal microbiome amplifies sex hormone-associated cyclic changes in cervicovaginal inflammation and epithelial barrier disruption. Am J Reprod Immunol, e12863 (2018).

38. N. Low et al., Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 8, e1000416 (2011).

39. J. Bilardi et al., Women's Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated with Recurrence. PLoS One 11, e0150272 (2016).

40. L. A. Vodstrcil et al., The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS One 12, e0171856 (2017).

41. D. S. Forcey et al., Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS One 10, e0141905 (2015).

42. M. Carda-Dieguez et al., Variations in Vaginal, Penile, and Oral Microbiota After Sexual Intercourse: A Case Report. Front Med (Lausanne) 6, 178 (2019).

43. M. Noormohammadi, G. Eslamian, S. N. Kazemi, B. Rashidkhani, Association between dietary patterns and bacterial vaginosis: a case-control study. Sci Rep 12, 12199 (2022).

44. S. Tuddenham et al., Associations between dietary micronutrient intake and molecular-Bacterial Vaginosis. Reprod Health 16, 151 (2019).

45. M. N. Mascarenhas, S. R. Flaxman, T. Boerma, S. Vanderpoel, G. A. Stevens, National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 9, e1001356 (2012).

46. W. Ombelet, I. Cooke, S. Dyer, G. Serour, P. Devroey, Infertility and the provision of infertility medical services in developing countries. Hum Reprod Update 14, 605-621 (2008).

47. B. J. Peipert et al., A Geospatial Analysis of Disparities in Access to Oncofertility Services. JAMA Oncol 9, 1364-1370 (2023).

48. "2015 Assisted Reproductive Technology Fertility Clinic Success Rates Report,"  (Atlanta (GA);  US Dept. of Health and Human Services, 2017).

49. A. M. Quaas, K. R. Hansen, The role of steroid hormone supplementation in non-assisted reproductive technology treatments for unexplained infertility. Fertil Steril 106, 1600-1607 (2016).

50. A. Quaas, A. Dokras, Diagnosis and treatment of unexplained infertility. Rev Obstet Gynecol 1, 69-76 (2008).

51. A. R. Berard et al., Understanding mucosal and microbial functionality of the female reproductive tract by metaproteomics: Implications for HIV transmission. Am J Reprod Immunol 80, e12977 (2018).

52. S. Altmäe, J. M. Franasiak, R. Mändar, The seminal microbiome in health and disease. Nature Reviews Urology 16, 703-721 (2019).

53. M. I. Petrova, E. Lievens, S. Malik, N. Imholz, S. Lebeer, Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol 6, 81 (2015).

54. A. Barbonetti et al., Effect of vaginal probiotic lactobacilli on in vitro-induced sperm lipid peroxidation and its impact on sperm motility and viability. Fertil Steril 95, 2485-2488 (2011).

55. J. M. Walboomers et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19 (1999).

56. J. G. Skeate, A. W. Woodham, M. H. Einstein, D. M. Da Silva, W. M. Kast, Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother 12, 1418-1429 (2016).

57. Z. Hu, D. Ma, The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 7, 5217-5236 (2018).

58. H. zur Hausen, Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2, 342-350 (2002).

59. H. W. Chesson, E. F. Dunne, S. Hariri, L. E. Markowitz, The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41, 660-664 (2014).

60. K. S. Okunade, Human papillomavirus and cervical cancer. J Obstet Gynaecol 40, 602-608 (2020).

61. C. Pingali et al., National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2020. MMWR Morb Mortal Wkly Rep 70, 1183-1190 (2021).

62. Y. Bird, O. Obidiya, R. Mahmood, C. Nwankwo, J. Moraros, Human Papillomavirus Vaccination Uptake in Canada: A Systematic Review and Meta-analysis. Int J Prev Med 8, 71 (2017).

63. R. Suk, K. Liao, C. X. Bauer, C. Basil, M. Li, Human Papillomavirus Vaccine Administration Trends Among Commercially Insured US Adults Aged 27-45 Years Before and After Advisory Committee on Immunization Practices Recommendation Change, 2007-2020. JAMA Health Forum 3, e224716 (2022).

64. L. K. Sycuro et al., Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 198, 971-978 (2008).

65. G. F. Sawaya, K. Smith-McCune, M. Kuppermann, Cervical Cancer Screening: More Choices in 2019. JAMA 321, 2018-2019 (2019).

66. A. Gutiérrez-Hoya, I. Soto-Cruz, NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy. Cells 10, (2021).

67. M. Murata, Inflammation and cancer. Environ Health Prev Med 23, 50 (2018).

68. S. J. Bowden et al., Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med 21, 274 (2023).

69. J. D. Sobel, Vulvovaginal candidosis. Lancet 369, 1961-1971 (2007).

70. B. Gonçalves et al., Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol 42, 905-927 (2016).

71. J. D. Sobel et al., Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. Infect Drug Resist 12, 2297-2307 (2019).

72. J. M. Achkar, B. C. Fries, Candida infections of the genitourinary tract. Clin Microbiol Rev 23, 253-273 (2010).

73. G. H. W. Tso, J. A. Reales-Calderon, N. Pavelka, The Elusive Anti-. Front Immunol 9, 897 (2018).

74. D. A. Eschenbach, Chronic vulvovaginal candidiasis. N Engl J Med 351, 851-852 (2004).

75. J. Marrazzo, Vulvovaginal candidiasis. BMJ 326, 993-994 (2003).

76. D. W. Denning, M. Kneale, J. D. Sobel, R. Rautemaa-Richardson, Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 18, e339-e347 (2018).

77. B. D. Reed, P. Zazove, C. L. Pierson, D. W. Gorenflo, J. Horrocks, Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health (Larchmt) 12, 979-989 (2003).